Disposable Components in Aseptic Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Disposable Components in Aseptic Processing
The authors discuss current and future disposable technologies and outline the validation and qualification steps that would be required for a possible disposable process stream.


Pharmaceutical Technology


Conclusion

Many disposable devices are already available, most commonly as a single entity, but in some instances already connected (e.g, filter–bag or bioreactor–filter systems). Rapidly developing connectivity will enhance the development of connected, integral systems and potentially total disposable processes, at least in small volume scales. Some developments (e.g., filling lines) are still necessary. The last step in aseptic processing has not reached the level one finds in the intermediate steps.

The benefits of disposability within aseptic processes are obvious. Cleaning deficiencies are a common regulatory observation, which would be eliminated by disposable equipment use. The risk of cross contamination is greatly reduced. Moreover, disposable, aseptic connectivity will reduce the level of end-user manipulation within the process and therefore create higher safety. Disposability is also valuable from economic and environmental standpoints because there is a cost savings in cleaning solutions and copious amounts of water, as well as the high energy levels required to heat the cleaning solutions or steam sterilize reusable equipment.

Maik W. Jornitz* is group vice-president of marketing FT/FRT at Sartorius Stedim,
. Jean-Marc Cappia is group vice-president of marketing FMT at Sartorius Stedim SA. Theodore H. Meltzer is principle of Capitola Consultancy.

*To whom all correspondence should be addressed.

Additional reading

  • M.W. Jornitz et al., "Testing for the Optimal Filter Membrane," Genetic Engineering News 24 (13) (July 2004).
  • J. Mora et al., "Disposable Membrane Chromatography: Performance Analysis and Economic Cost Model," BioProcess Int. 4, 38–43 (2006).
  • PDA Technical Report 26: Liquid Sterilizing Filtration (Parenteral Drug Association, Bethesda, MD, 2008).
  • M. Prashad and K. Tarrach "Depth Filtration Aspects for the Clarification of CHO Cell-Derived Biopharmaceutical Feed Streams," FISE 9, 28–30 (2006).
  • P.M. Priebe, "Advances in Fluid Processing Technologies," presented at the PDA SciTech Conference, Orlando, March 2004.
  • M. Rios, "Disposable Filtration Lightens Cleaning and Validation Load," Pharm. Technol. 25 (9), (2003).
  • A. Sinclair and M. Monge, "Quantitative Economic Evaluation of Single Use Disposables in Bioprocessing," Pharma. Eng. 22 (3), 16–20 (May–June 2002).
  • J.X. Zhou and T. Tressel, "Membrane Chromatography as a Robust Purification System for Large-Scale Antibody Production," BioProcess Int. 3, 32–37 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here